BioCardia announced that the Japanese Patent Office has granted an allowance for its Heart3D™ Fusion Imaging software, a tool that overlays pre‑operative CT or MRI heart models onto real‑time X‑ray images to guide intramyocardial delivery during CardiAMP procedures.
The patent covers the software’s ability to transpose a three‑dimensional cardiac image onto two orthogonal two‑dimensional displays, creating a combined 3‑D model that can be viewed within a sterile field. By securing this patent, BioCardia protects a key component of its therapeutic workflow, reinforcing the intellectual‑property foundation for its cell‑therapy platform and Helix delivery system and opening the door to future licensing or partnership opportunities in Japan and other markets.
The Heart3D software was developed in collaboration with corporate partner CART‑Tech, and the patent allowance comes as BioCardia continues to advance regulatory engagement. The company’s CardiAMP Cell Therapy has received FDA Breakthrough designation, and BioCardia is preparing to submit product candidates to the Japanese Pharmaceutical and Medical Device Agency (PMDA) while scheduling FDA meetings in May 2026 to discuss the Helix delivery catheter and CardiAMP Cell Therapy in the United States.
In the highly competitive field of cardiac cell therapy, securing a patent in a major market such as Japan strengthens BioCardia’s competitive position, signals robust IP protection to investors and partners, and supports the company’s long‑term strategy of expanding its technology platform across multiple regulatory jurisdictions.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.